Global Gout Therapeutic Market: Trends, Size & Growth (2019-2027) – ResearchAndMarkets.com
November 26, 2019DUBLIN–(BUSINESS WIRE)–The “Gout Therapeutic Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019-2027” report has been added to ResearchAndMarkets.com’s offering.
This report studies the current as well as future prospects of the global gout therapeutics market. Stakeholders of this report include companies and intermediaries engaged in the manufacture, commercialization, and provision of gout therapeutics and new players planning to enter the market.
The report comprises an elaborate executive summary, along with a market snapshot, providing overall information on various segments considered in the scope of the study. The section also provides information and data analysis of the global gout therapeutics market in terms of drug type, distribution channel, and region.
Key Segments
The global gout therapeutics market has been segmented based on drug type, distribution channel, and region. In terms of drug type, the global market has been classified into colchicine, antihyperuricemic agents (urate-lowering drugs), non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and biologic response modifiers (Biologics).
Based on distribution channel, the global gout therapeutics market has been divided into hospital pharmacy, retail pharmacy, and online pharmacy. The retail pharmacy segment is expected to dominate the global gout therapeutics market during the forecast period.
Research Approach
The bottom-up approach has been employed to determine the size of the global gout therapeutics market, using various market indicators obtained from secondary sources, which included analysis of launched products and mapping of demand for gout therapeutics of top market players in specific regions.
The top-down approach has been used to derive the market size of different product segments, wherein market size of parent market was obtained through secondary sources and analyzed for sales by narrowing down to revenue percentage for product segment through extensive analysis of investor presentations, press releases, primary interviews, and others.
Data triangulation is based on both secondary research (top-down and bottom-up approaches) and primary research. Moreover, historical year-on-year growth has been taken into consideration while estimating the market size. Market value and forecast, in terms of US$ Mn, for each segment has been provided for the period from 2017 to 2027.
The report also provides compound annual growth rate (CAGR %) for each segment for the forecast period from 2019 to 2027, considering 2018 as the base year.
The overview section of the report explores market dynamics such as drivers, restraints, opportunities, and key trends that have significant impact on the global gout therapeutics market and could influence it in the near future.
Market attractiveness analysis has been provided to explain the intensity of competition in the market across regions. These analyses are likely to help market players take strategic decisions to strengthen their positions and grow their share in the global gout therapeutics market. The report also comprises pipeline analysis and epidemiological overview of gout.
Regional Outlook
In terms of region, the global gout therapeutics market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Market size and forecast for each of these regions have been provided for the period from 2017 to 2027, along with their respective CAGRs for the forecast period from 2019 to 2027, considering 2018 as the base year.
The report also provides market size and forecast for major countries in the above mentioned regions. A detailed qualitative analysis of factors responsible for driving and restraining the market and growth opportunities has been provided in the overview section.
Companies Profiled
- Takeda Pharmaceutical Company Limited
- Teijin Pharma Limited
- Novartis AG
- Mylan N.V.
- Horizon Pharma plc
- Teva Pharmaceutical Industries Ltd.
- Hikma Pharmaceuticals PLC
- Iroko Pharmaceuticals LLC
- Merck & Co. Inc.
For more information about this report visit https://www.researchandmarkets.com/r/3555bz
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900